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Recently, chronic myeloid leukemia (CML) patients already responding to treatment showed improved
molecular responses with pioglitazone, presumably through PPARg activation and CML stem cell eradica-
tion. Given data demonstrating deepening responses and successful treatment discontinuation with current
therapy, the necessity for new therapies targeting CML stem cells to achieve cure is unclear.Chronic myeloid leukemia (CML) is a
myeloproliferative neoplasm character-
ized by the presence of the Philadelphia
chromosome (Ph), an abnormality created
by a reciprocal chromosomal transloca-
tion. The resultant BCR-ABL fusion gene
encodes a constitutively active tyrosine
kinase. Selective BCR-ABL tyrosine ki-
nase inhibitors (TKIs), including imatinib,
dasatinib, and nilotinib, are highly active
first line agents for CML. Most CML pa-
tients respond deeply to TKI therapy and
have good clinical outcomes, but they
typically have detectable BCR-ABL tran-
script during the first few years of treat-
ment (Bhatia et al., 2003; Chu et al.,
2011). As a consequence, indefinite treat-
ment is recommended, increasing costs
and toxicity.
The inability of TKIs to rapidly eradicate
disease is largely attributed to persis-
tence of CML stem cells that are not
strongly ‘‘addicted’’ to BCR-ABL kinase
activity. TKI treatment of primary CML
cells ex vivo fails to kill quiescent CML
stem cells, although assays are typically
performed over short periods (days to
weeks). More notably, CML patients
treated with imatinib for years harbor
Ph+ stem cells that can populate the
marrow of nude irradiated mice (Chu
et al., 2011; Graham et al., 2002). These
and other data led many to believe imati-
nib kills dividing CML cells but cannot
penetrate the quiescent CML stem cell
pool, which theoretically needs to be
eradicated to effect cure.
A wave of research ensued to identify
druggable pathways that might be selec-
tively critical for CML stem cell survival.
Over the past 7 years, an abundance ofpathways, signaling proteins, and tran-
scriptional regulators—including Hedge-
hog (Hh), Notch, Wnt, CAMK2, Bmi1,
GABP, pRKD2, GATA2, JAK, FBXW7,
SIRT1, AHI-1, and the autophagy
pathway—have been implicated as crit-
ical for CML stem cell survival in various
model systems (Zhou and Xu, 2015). The
parallel development of active clinical Hh
pathways inhibitors (e.g., vismodegib)
made assessing the importance of Hh in-
hibition in CML patients opportune. Un-
fortunately, Hh pathway inhibitors tested
were unsuccessful. Patients suffered dis-
tressing side effects that strongly sug-
gested on-target inhibition (alopecia,
loss of taste, muscle cramping), but had
no significant clinical benefit. Although a
number of studies investigating other
pathways continue, none have yet re-
ported convincing evidence of success.
Collectively, these experiences call into
question the validity of current models to
study CML stem cells. Additionally, it is
difficult to fathom how most or all of the
pathways implicated could be critical for
CML stem cell survival. Clinical proof-of-
concept is paramount to placate these
concerns.
In the September 17th issue of Nature,
Prost et al. (2015) implicated PPARg as
a novel critical node for CML stem cell
survival. The study was inspired by the
clinical observation that patients infected
with immunodeficiency viruses develop
pancytopenia throughmyelosuppression.
The authors of the study previously
showed the mechanism of pancytopenia
involves Nef proteins that activate PPARg
(Prost et al., 2008). As a part of this work,
the authors showed that glitazones, directCancer Cell 28agonists of PPARg that are FDA-
approved treatments for diabetes, block
growth of the CML K562 cell line. Prost
and colleagues have extended these
findings to show glitazones can affect
CML stem cells. Interestingly, activation
of PPARg with glitazones stimulates
CML stem cells to exit quiescence, and
glitazones thereby act synergistically
with imatinib to eradicate both dividing
CML cells and non-dividing CML stem
cells. The paper provides compelling
evidence that the molecular mechanism
involves decreased transcription of
STAT5, a well-described direct target
downstream of BCR-ABL kinase and a
key signaling molecule in several myelo-
proliferative neoplasms (MPNs). They
further trace the mechanism to downre-
gulation of HIF2a, which is normally
upregulated and vital in stem cells, and
downregulation of the HIF2a effector
CITED2 and several CITED2 target genes.
The authors conclude the PPARg-STAT5-
HIF2a-CITED2 pathway is critically upre-
gulated in CML stem cells andmodulation
of the pathway with glitazones can act
synergistically with imatinib to gradually
deplete the CML stem cell pool (Figures
1A and 1B).
Given the pervasive historic difficulty
translating CML stem cell vulnerabilities
to the clinic, the clinical data in the
study deserve careful scrutiny. The au-
thors selected three chronic phase CML
patients with detectable BCR-ABL
transcripts despite years of continuous
imatinib. These patients were already in
significant molecular remission, with
BCR-ABL transcripts % 0.1%. After pio-
glitazone was added to their treatment,, October 12, 2015 ª2015 Elsevier Inc. 409
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Figure 1. Piolitazone Synergizes with Imatinib, But TKIs Alone Deplete BCR-ABL Transcripts over Time
(A) Imatinib is effective against dividing CML cells, but not CML stem cells.
(B) Pioglitazone makes CML stem cells accessible to imatinib by decreasing STAT5 transcription, thus decreasing signals that maintain stem cell quiescence.
Double red lines, resistance; orange lines, transcriptional regulation; weight of line indicates strength of signal (dashed line, weakest; bold line, strongest).
(C) BCR-ABL transcripts decrease with time in patients on continuous imatinib therapy, making the benefit of adding pioglitazone to imatinib unclear.
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remission (CMR), meaning no detect-
able BCR-ABL by PCR; however, CMR
achievement took 6–12 months.
Was CMR achieved in these patients
because of pioglitazone or were these pa-
tients likely to achieve CMR regardless of
the addition of pioglitazone? A phase II
clinical trial provocatively showed that
12 months after trial initiation patients
treated with imatinib plus pioglitazone
had 57% CMR compared with 21% of
historical imatinib-only controls. How-
ever, comparison with historical controls
can be problematic, and few trial details
are presented. A randomized controlled
trial is essential to provide definitive clin-
ical proof-of-concept.
Several issues engender a healthy
skepticism about the significance of the
findings. Treatment with imatinib typically
causes steep initial decline of BCR-ABL
transcript level, then the decline becomes
more gradual (Tang et al., 2011). Also,
it is well-established that molecular re-
sponses in many CML patients gradually
deepen over time, with the proportion
who achieve an undetectable level of
BCR-ABL increasing from approximately
3%–10% after 1 year to 30%–50%410 Cancer Cell 28, October 12, 2015 ª2015after 5 years of TKI therapy (G. Saglio
et al., 2013, Am. Soc. Hematol., abstract)
(Figure 1C). It is therefore unclear if piogli-
tazone contributed to deeper molecular
responses in patients already responding
well to imatinib.
Additionally, approximately 50% of pa-
tients in a TKI-induced sustained CMR
can interrupt therapy without suffering
persistently rising BCR-ABL transcript
for at least several years. The pioneering
STIM (Stop Imatinib) study demonstrated
41%of CML patients in CMRwho discon-
tinued imatinib continued to be in CMR af-
ter 12months (Mahon et al., 2010). Longer
follow-up demonstrates these treatment-
free remissions typically persist for at
least 5 years. A possible explanation for
successful treatment discontinuation is
that TKIs alone cause gradual eradication
of CML stem cells. Alternatively, control of
minimal residual disease through an im-
mune surveillance mechanism may be
operative. More work is needed to un-
cover the central mechanism(s).
For CML patients and researchers, the
data on pioglitazone are provocative, but
caution is warranted. It is difficult to justify
exposing patients who already have
highly active generally safe TKI treatmentElsevier Inc.options to pioglitazone, which has been
linked to bladder cancer and has side ef-
fects including hypoglycemia, heart fail-
ure, and liver disease. CML today is a
chronic disease. The minimally toxic oral
long-term treatments enable most pa-
tients to have an acceptable quality
of life and may effect cure. Therefore,
despite the apparent inability of TKIs to
eradicate CML stem cells in model sys-
tems, the bar for adding treatment in
most cases is high. Given the large num-
ber of clinical trials with BCR-ABL TKIs
to date, it will be interesting to see if retro-
spective analyses of CML patients taking
PPARg agonists are supportive of a salu-
tary effect on molecular response.
Perhaps the greatest significance of the
Prost et al. (2015) findings is that it may
provide a tool to study diseases driven
by STAT5 signaling. For example, large
granular lymphocyte leukemia (LGL) is a
rare T cell malignancy genetically driven
by activation of STAT signaling, with
STAT5b mutations in a minority of pa-
tients (Rajala et al., 2013). In contrast to
LGL driven by other mutations, such as
the 40% driven by STAT3 mutations,
STAT5b mutated LGL is more aggressive
and difficult to treat. Pioglitazone may
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pathogenesis of LGL and other MPNs re-
ported to be reliant on STAT5 signaling,
such as polycythemia vera, essential
thrombocythemia, and myelofibrosis.
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The complex tumor microenvironment can make molecularly subtyping cancer using mRNA expression
challenging, particularly for cancers with low epithelial content, such as pancreatic cancer. In a recent edition
of Nature Genetics, Moffitt and colleagues show that subtracting normal epithelial transcripts can provide
insights into the molecular pathology of pancreatic cancer.Pancreatic ductal adenocarcinoma
(PDAC) continues to be the fourth leading
cause of cancer death in our society, with
little if any improvement in outcomes for
over 40 years. Systemic therapies offer
only incremental overall survival advan-
tages but can be associated with signifi-
cant responses in subgroups of patients
that cannot be predicted prior to treat-
ment. As a consequence, there is an
urgent need to better define subgroups
of patients that derive benefit from current
treatment and identify novel therapeutic
strategies. Recent large-scale cancer
genomic studies demonstrate a heteroge-
neous mutational profile, with activating
mutations of KRAS present in over
90%, mutations of TP53, CDKN2A, and
SMAD4 in over 50% of cases among asea of diverse infrequently mutated genes
mostly at a prevalence of less than 5%
(Biankin et al., 2012; Waddell et al.,
2015; Witkiewicz et al., 2015). Although
some studies report potential prognostic
and predictive genomic markers, few
have been validated and none are used
in the clinic. A recent issue of Nature
Genetics presented an article by Moffitt
et al. (2015), who assessed aberrant
gene expression in pancreatic cancer
to define molecular subtypes of tumor
epithelium and stroma, with some fea-
tures associated with patient outcome.
Expression profiling has defined sub-
types in many cancer types, including
breast and ovarian cancer, often with
clinical relevance and usually the result
of many studies that validated and refinedinitial findings. The density of mRNA
expression information overcomes the
relative diversity and sparseness of
genomic mutation data to allow the
modeling of differential expression relative
to clinico-pathological attributes. A char-
acteristic feature of PDAC is the abundant
stroma, which, on average, constitutes
over 70% of the tumor mass. In addition,
PDAC’s infiltrative nature means that
the tumor can include normal pancreas
(containing exocrine epithelium that se-
cretes digestive enzymes and endocrine
cells that secrete digestive hormones,
including insulin and glucagon as well as
a variety of others). These factors have
made defining molecular subgroups and
identifying carcinogenic mechanisms
based on mRNA expression challenging., October 12, 2015 ª2015 Elsevier Inc. 411
